RxDoctor Payments Data

William Gannon, MD

Ophthalmology · Dothan, ALNPI 1275978850

Payments from drug & device makers

$1,526in general payments, 2019–2025

Across 60 payments — averaging $25.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$232
  • Bausch & Lomb Americas Inc.$199
  • Johnson & Johnson Surgical Vision, Inc.$197
  • Alcon$117
  • Kala Pharmaceuticals, Inc.$101
  • Sun Pharmaceutical Industries Inc.$93
  • plus $587 from 13 others

What the payments were for

  • Food & beverage$1,51099%
  • Entertainment$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,526 in reported general payments places this provider in the 45th percentile of 197 ophthalmology providers in Alabama.

See all ophthalmology providers in Alabama

Medicare billing

Part B allowed, 2024
$426,694
Medicare patients
727
Services billed
2,794

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProlensaBromfenac Sodium388$136,152
RestasisCyclosporine63$44,031
IlevroNepafenac110$40,840
LumiganBimatoprost49$20,330
XiidraLifitegrast15$19,179
Bromfenac Sodium74$15,664
Cyclosporine26$13,308
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha785$10,648
Latanoprost277$4,392
Travoprost32$3,845
CombiganBrimonidine Tartrate/Timolol12$3,523
Loteprednol Etabonate18$2,945
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat156$2,910
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol12$2,798
SimbrinzaBrinzolamide/Brimonidine Tart12$2,570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$82$139,097406 claims
AbbVieRestasis, Lumigan, Combigan$74$67,884124 claims
NovartisIlevro$232$40,840110 claims
Bausch & Lomb Americas Inc.Xiidra$199$19,17915 claims
AlconSimbrinza$117$2,57012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 197 ophthalmology providers in Alabama.

Other ophthalmology in Dothan

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →